- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Zoptarelin Doxorubicin Shows Promise in Patients With Endometrial Cancer
Hybrid molecule consists of peptide carrier and chemotherapy agent (February 4)
Promising phase II data on zoptarelin doxorubicin (AEZS-108, Aeterna Zentaris) in endometrial cancer have been published in the February issue of the International Journal of Gynecological Cancer.
Forty-three women with advanced or recurrent luteinizing hormone-releasing hormone (LHRH) receptor-positive endometrial cancer were evaluated in a European study. Two patients (5%) experienced complete remission, and eight (18%) achieved partial remission. Stable disease for at least 6 weeks was observed in 19 patients (44%). The median time to progression was 7 months, and median overall survival was 15 months. The most frequently reported grade-3 or -4 adverse effects were neutropenia (12%) and leukopenia (9%).
Zoptarelin doxorubicin is a hybrid molecule consisting of a synthetic peptide carrier and a commonly used chemotherapy agent, doxorubicin. It is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH receptor-expressing tumors.
Endometrial cancer is the most common gynecologic malignancy in developed countries. The disease largely affects women over the age of 50 years, with a higher prevalence in Caucasians and a higher mortality rate in African-Americans. According to the American Cancer Society, an estimated 49,560 new cases of endometrial cancer were expected to occur in the U.S. in 2013.
Source: Aeterna Zentaris; February 4, 2014.